Factor XI antibodies and methods of use

US10465011B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Jorg Eder · Rheinfelden (Baden), DE
• Stefan Ewert · Basel, CH
• Ulrich Hassiepen · Bad Kötzting, DE
• Yasser KHDER · Hésingue, FR
• Lorenz Mayr · Bingen, DE
• Samu Melkko · Zürich, CH
• Nikolaus SCHIERING · Weil am Rhein, DE

Key dates

• Filing date: Jun 24, 2016
• Grant date: Nov 5, 2019
• Expiry date: Feb 22, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.